Retatrutide vs Cagrilintide: Research Comparison
A Side-By-Side Research Comparison Of Retatrutide And Cagrilintide - a triple incretin agonist versus an amylin analog in weight research. This Reference Compares Mechanism, Evidence Tier, Molecular Identity, And Pharmacokinetics For Qualified Researchers. For In Vitro Laboratory Research Use Only. Not Medical Advice Or Dosing Guidance.
Side-By-Side Comparison
| Retatrutide | Cagrilintide | |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Compound Class | Synthetic triple agonist: GIP receptor + GLP-1 receptor + glucagon receptor | Long-acting synthetic amylin analog (fatty acid-conjugated for once-weekly dosing) |
| Evidence Tier | Investigational | Investigational |
| Molecular Target | GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect | Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation |
| Molecular Weight | 4731.3 Da | 4409.01 Da |
| Amino Acid Sequence | 39-aa GIP/GLP-1/glucagon tri-agonist (acylated) | acylated cyclic amylin analog |
| CAS Number | 2381089-83-2 | 1415456-99-3 |
| Half-Life | ~1 week | ~1 week (weekly SC, acylated) |
| Studied For | Obesity / overweight, Type 2 diabetes, Liver fat / MASLD / NAFLD, Triple agonist weight loss | Obesity / overweight, Type 2 diabetes, Combination with semaglutide (CagriSema), Amylin receptor agonism for satiety |
About Retatrutide
An investigational triple-agonist weight-loss peptide with strong early trial results.
Read The Full Retatrutide MonographAbout Cagrilintide
An investigational amylin weight-loss peptide, often paired with semaglutide.
Read The Full Cagrilintide MonographKey Differences
- Reported half-life differs: Retatrutide at ~1 week versus Cagrilintide at ~1 week (weekly SC, acylated).
- Primary molecular target differs: Retatrutide acts on GIPR (GIP receptor) + GLP-1R (GLP-1 receptor) + GCGR (glucagon receptor); triple incretin/glucagon signaling for maximal metabolic effect; Cagrilintide acts on Amylin receptor (AMY1-3, CTR + RAMP1/2/3 complexes) and calcitonin receptor (CTR); hypothalamic satiety signaling; gastric motility modulation.
Continue Researching
Retatrutide · Cagrilintide · Compare Tool · Research Library
This Comparison Is Provided For In Vitro Laboratory Research Use Only. Not For Human Consumption, Diagnosis, Or Treatment. See The Full Research Disclaimer.